Product Description
Mechanisms of Action: PBP Inhibitor, Cell Wall Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Brazil | Chile | Colombia | Dominican Republic | India | Ireland | Italy | Mexico | Morocco | New Zealand | Pakistan | Peru | Russia | South Africa | Taiwan | Turkey | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Cabrini Research and Education Institute and Monash University
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| NEM-2011/2296 | N/A |
Unknown status |
Femoral Neck Fractures|Femoral Fractures |
2020-02-06 |
2020-02-09 |
||
| ACTRN12605000079640 | N/A |
Completed |
Osteoporotic Fractures|Osteoporosis |
2008-10-30 |
2024-04-03 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|